Vaccine and Immunotherapy Center, Massachusetts General Hospital, Boston, MA, United States.
EpiVax, Inc., Providence, RI, United States.
Front Immunol. 2022 May 16;13:901372. doi: 10.3389/fimmu.2022.901372. eCollection 2022.
T cell-mediated immunity plays a central role in the control and clearance of intracellular infection, which can cause Q fever. Therefore, we aimed to develop a novel T cell-targeted vaccine that induces pathogen-specific cell-mediated immunity to protect against Q fever in humans while avoiding the reactogenicity of the current inactivated whole cell vaccine. Human HLA class II T cell epitopes from were previously identified and selected by immunoinformatic predictions of HLA binding, conservation in multiple isolates, and low potential for cross-reactivity with the human proteome or microbiome. Epitopes were selected for vaccine inclusion based on long-lived human T cell recall responses to corresponding peptides in individuals that had been naturally exposed to the bacterium during a 2007-2010 Q fever outbreak in the Netherlands. Multiple viral vector-based candidate vaccines were generated that express concatemers of selected epitope sequences arranged to minimize potential junctional neo-epitopes. The vaccine candidates caused no antigen-specific reactogenicity in a sensitized guinea pig model. A subset of the vaccine epitope peptides elicited antigenic recall responses in splenocytes from C57BL/6 mice previously infected with However, immunogenicity of the vaccine candidates in C57BL/6 mice was dominated by a single epitope and this was insufficient to confer protection against an infection challenge, highlighting the limitations of assessing human-targeted vaccine candidates in murine models. The viral vector-based vaccine candidates induced antigen-specific T cell responses to a broader array of epitopes in cynomolgus macaques, establishing a foundation for future vaccine efficacy studies in this large animal model of infection.
T 细胞介导的免疫在控制和清除细胞内感染中起着核心作用,这种感染可能导致 Q 热。因此,我们旨在开发一种新型的 T 细胞靶向疫苗,该疫苗能诱导针对病原体的细胞介导免疫,以保护人类免受 Q 热的侵害,同时避免当前灭活全细胞疫苗的反应原性。先前通过对 HLA 结合的免疫信息学预测、多种 分离株的保守性以及与人类蛋白质组或微生物组交叉反应的低潜力,从 中鉴定和选择了人类 HLA Ⅱ类 T 细胞表位。根据个体在荷兰 2007-2010 年 Q 热爆发期间自然接触细菌时对相应肽的长寿命人类 T 细胞回忆反应,选择表位用于疫苗纳入。生成了多种基于病毒载体的候选疫苗,这些疫苗表达了所选表位序列的串联体,排列方式可最大程度地减少潜在的连接新表位。候选疫苗在致敏豚鼠模型中不会引起抗原特异性的反应原性。在先前感染过 的 C57BL/6 小鼠的脾细胞中,疫苗表位肽的亚组引起了抗原性回忆反应。然而,疫苗候选物在 C57BL/6 小鼠中的免疫原性主要由一个表位主导,这不足以赋予对感染挑战的保护,突出了在鼠模型中评估针对人类的疫苗候选物的局限性。基于病毒的疫苗候选物在食蟹猴中诱导了针对更广泛表位的抗原特异性 T 细胞反应,为在这种感染的大型动物模型中进行未来疫苗功效研究奠定了基础。